We are exploring actively numerous novel targets for the therapy of pancreas and breast cancer.
One novel target is anaplastic lymphoma kinase (ALK). ALK can be oncongenic when fused with other genes (e.g, EML4-ALK in lung cancer). However, we have identified that ALK activity in tumor associated macrophages drives a pro-metastatic macrophage phenotype and further inhibition of ALK in macrophages can augment that activity of other therapy such as anti-VEGF strategies. The Mary Kay Foundation has recently funded our Lab to explore the use of ALK as a marker of breast cancer progression and as a target for therapy.